Intrexon | XON - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Agenus USD 35.32M 2.51M 2025-12
Alaunos Therapeutics USD 2.21M 131K 2025-09
Amgen USD 540M 1000K 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 137.39M 1.69M 2025-12
AstraZeneca USD 1.55B 73K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Incyte USD 199.95M 1.49M 2026-03
Intrexon USD 0 0 2024-06
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.32M 60K 2025-12
MannKind USD 308.91M 1.07M 2026-03
Merck USD 2.47B 12.72M 2025-12
Novartis USD 1.91B 60K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Roche Holding CHF 795.62M 699.54K 2025-12
Thermo Fisher Scientific USD 371.62M 4.09M 2026-03
Veracyte USD 79.79M 743K 2026-03
Xencor USD 74.06M 2.19M 2026-03